As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage

JPMA President Joji Nakayama As Japan plans to delineate the scope of so-called “off-year” re-pricing this year before the new revision cycle begins in April 2021, pharma industry leader Joji Nakayama urges the government to limit its coverage to a...read more